ClinicalTrials.gg
Not yet recruitingNCT07852013Updated Nov 18, 2026

Eye-Tracking Alcohol Warning

An interventional study of Alcohol Cancer Warning Labels in Alcohol, sponsored by University of Miami. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Miami · Not applicable, Interventional, and Basic science

How we know

Updated Nov 18, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

This pilot study will evaluate communication strategies that may improve public understanding of alcohol-related cancer risks and influence behavioral intentions. The study will compare graphic alcohol cancer warning labels with the current U.S. Surgeon General text-only warning label across two stages. The first stage is an in-person, lab-based eye-tracking experiment that will examine differences in visual attention, communication outcomes, harm perception, and behavioral intentions following exposure to graphic versus text-only warning labels. The second stage is a discrete choice experiment that will examine how warning label type, warning label size, and alcohol type (beer, wine, or liquor) influence participants' intentions to reduce or stop alcohol consumption and purchase alcohol. The study will recruit 50 adults aged 21 years or older who report regular alcohol consumption.

02

Conditions studied

  • Alcohol

Browse trials for

Keywords

  • Cancer
  • Alcohol Warning Labels
  • Graphic Warning Labels
  • Eye-Tracking
  • Discrete Choice Experiment
  • Cancer Risk Communication
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 21 years
  • Regular alcohol consumers (≥ 2 drinks per week)
  • US residence
  • Able to read and understand English
  • Able and willing to provide
  • Able to wear eyeglasses

Exclusion criteria

Exclusion Criteria:

  • Are not regular alcohol consumers (\< 2 drinks per week)
  • Are unable to complete study procedures due to cognitive or physical limitations
  • Decline or withdraw
  • Pregnant women, prisoners, persons not residing in the US, and non-alcohol users
  • Have eye conditions or impairments that prevent reliable eye-tracking (e.g., severe nystagmus or uncorrectable visual impairment)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Alcohol Warning Label Exposure

    Participants will complete a 2-stage behavioral experiment during a single study visit. Stage 1 Eye-Tracking Experiment: Participants will complete an eye-tracking experiment during which they will view six alcohol warning-label stimuli presented one at a time in a randomized, counterbalanced order. The stimuli include graphic and text-only warning labels displayed on beer, wine, and liquor containers. Stage 2 Discrete Choice Experiment: Following completion of the eye-tracking experiment, participants will complete a discrete choice experiment consisting of 18 randomly presented choice sets that vary by warning label type, warning label size, and alcohol type. Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics.

    Behavioral: Alcohol Cancer Warning Labels

Interventions

  • BehavioralAlcohol Cancer Warning Labels

    Participants will be exposed to alcohol-cancer warning labels during two sequential study states. Stage 1 consists of Eye-Tracking Experiment in which participants will be exposed to six alcohol warning-label stimuli, including graphic alcohol cancer warning labels and Surgeon General text-only warning labels displayed on beer, wine, and liquor containers. Each participant will view all six warning-label stimuli for 15 seconds each in a randomized, counterbalanced order while visual attention is measured using eye-tracking technology. Stage 2 consist of the Discrete Choice Experiment in which participants will choose between 18 randomly presented choice sets. Choice sets will vary by warning label type, warning label size, and alcohol type (beer, wine, or liquor). Participants' responses will be used to assess preferences and behavioral reactions to different alcohol warning-label characteristics.

06

What researchers measure

Primary outcomes

  1. Visual Attention Metrics

    Visual attention to predefined areas of interest (AOIs) containing graphic and text-only alcohol warning labels on alcohol beverage container stimuli will be assessed using eye-tracking. Outcome measures include: (1) time to first fixation (milliseconds), defined as the elapsed time from stimulus presentation to the participant's first fixation on an AOI; (2) visit count, defined as the number of visits to an AOI; and (3) dwell time (milliseconds), defined as the cumulative duration of fixations within an AOI. Higher visit counts and dwell times indicate greater visual attention to the warning label.

    Time frame: During Stage 1 of the single study visit, approximately 35-45 minutes

  2. Intention to Reduce Alcohol Consumption in the Next 30 Days

    Participants will select between warning label alternatives that vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency or probability of selecting warning label alternatives perceived as most likely to increase intentions to reduce alcohol consumption within the next 30 days.

    Time frame: During Stage 2 of the single study visit, approximately 10-20 minutes

Secondary outcomes

  1. Emotional Reactions to Alcohol Warning Labels

    Emotional reactions following exposure to the warning labels will include believability, avoidance, cognitive elaboration, and negative affective responses. Believability will be assessed on a scale from 1 (strongly disagree) to 5 (strongly agree). Avoidance will be assessed as yes/no. Cognitive elaboration will be assessed using three items on a scale from 1 (not at all) to 5 (very much), with higher scores indicating greater cognitive processing of the warning label message.. Negative affect will be assessed using five items on a scale from 1 (not at all) to 5 (very much),with higher scores indicating greater negative emotional response.

    Time frame: After each warning-label exposure during Stage 1 of the single study visit, approximately 35-45 minutes

  2. Change in Harm Perception

    Change in harm perception will be assessed with one item asking how worried the participant is that alcohol drinking puts them at risk of cancer in the future, on a scale from 1 (not worried) to 5 (very worried).

    Time frame: "Baseline" or "Day 1"

  3. Change in Behavioral Intentions Toward Alcohol Consumption

    Change in behavioral intentions will be assessed with three items asking to what extent participants are determined to (i) reduce, (ii) completely stop, and (iii) commit to limiting their alcohol intake in the next 30 days, on a scale from 0 to 5, with higher scores indicating stronger intentions to modify alcohol consumption

    Time frame: "Baseline" or "Day 1"

  4. Intention to Stop Alcohol Consumption in the Next 30 Days

    Participants will select the warning label option most likely to increase their intention to stop alcohol consumption in the next 30 days. Warning label alternatives vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency of selecting warning label alternatives perceived as most likely to increase intentions to stop alcohol consumption within the next 30 days.

    Time frame: During Stage 2 of the single study visit, approximately 10-20 minutes

  5. Intention to Purchase Alcohol Products in the Next 30 Days

    Participants will select the warning label option most likely to decrease their intention to purchase alcohol products in the next 30 days. Warning label alternatives vary by warning label type, warning label size, and alcohol type. The outcome will be measured as the frequency of selecting warning label alternatives perceived as most likely to decrease intentions to purchase alcohol products within the next 30 days.

    Time frame: During Stage 2 of the single study visit, approximately 10-20 minutes

07

Study locations

1 site
  • University of Miami - Rosenstiel Medical Science Building
    Miami, Florida 33136, United States
    • Taghrid Asfar, Principal Investigator, MD, MPH · Contacttasfar@miami.edu · (305) 243-3826
    • Maria Fernanda Garcia Morillo, B.S. · Contactmfg136@med.miami.edu · 5615697987
    • Olusanya Oluwole · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 11 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Start moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, last on Nov 18, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2027 → Nov 2027, on Nov 18, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2027 → Dec 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 1, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
Nov 1, 2027was Oct 2027
CompletionEst.
Dec 1, 2027was Oct 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Dec 2026
moved 2 times, Oct 20, 2026 – Nov 18, 2026
Primary completion
Oct 1, 2027→Nov 1, 2027
Nov 18, 2026
Study completion
Oct 1, 2027→Dec 1, 2027
Nov 18, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 3 updates
  1. Nov 18, 2026
    Start date Nov 2026→Dec 2026
    Primary completion Oct 1, 2027→Nov 1, 2027
    Study completion Oct 1, 2027→Dec 1, 2027
    + 1 other change: contact details
  2. Oct 20, 2026
    Start date Oct 2026→Nov 2026
    + 1 other change: contact details
  3. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852013
Responsible party
Taghrid Asfar (Professor, University of Miami) — Principal investigator
First posted
Oct 1, 2026
Start date
Dec 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Taghrid Asfar, MD, MSPH
Contact
tasfar@miami.edu
(305) 243-3826
Taghrid Asfar, MD, MSPH
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion